（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 1 背景 董事會宣佈，於2025年11月3日，本公司與浦發銀行煙台分行訂立浦發銀行理財 產品協議，據此本公司同意以人民幣400.0百萬元的閒置自有資金向浦發銀行煙台 分行購買理財產品。 浦發銀行理財產品協議 （股份代號：9995） 須予披露交易 購買理財產品 購買理財產品 本公司第二屆董事會第二十一次會議已於2025年3月27日審議批准了關於使用 自有資金進行現金管理的決議，根據該決議本公司可使用不超過人民幣500.0百 萬元額度的部分閒置自有資金購買保本型銀行理財產品。 董事會宣佈，於2025年11月3日，本公司與浦發銀行煙台分行訂立浦發銀行理 財產品協議，據此本公司同意以人民幣400.0百萬元的閒置自有資金向浦發銀行 煙台分行購買理財產品。 上市規則的涵義 由 ...

Group 1 - The report emphasizes a strategic focus on the "15th Five-Year Plan," indicating that the most significant overseas disturbances may be gradually passing, with domestic factors such as the Fourth Plenary Session and third-quarter report verification likely to boost market risk appetite [3][9][11] - The report highlights the importance of technology growth sectors, particularly AI, military industry, and innovative pharmaceuticals, as key areas for investment opportunities [2][12][13] - The AI sector is identified as a focal point, with a focus on the global computing power supply chain and domestic innovation, particularly in GPU and semiconductor equipment [12][13] Group 2 - The military industry is expected to enter a new cycle of prosperity, supported by the "15th Five-Year Plan," which emphasizes national strategic deployment and the release of new orders [12][13] - The innovative pharmaceutical sector has seen sufficient emotional digestion, with expectations for revaluation driven by business development and global monetary easing [12][13] - The report includes a selection of "golden stocks" for November, including Tianshan Aluminum, Weiming Environmental Protection, and Sany Heavy Industry, among others, with a focus on their growth and value potential [4][8][19][22][33] Group 3 - Tianshan Aluminum reported a revenue of 22.32 billion yuan for the first three quarters of 2025, with a year-on-year growth of 7.3%, and a net profit of 3.34 billion yuan, reflecting an increase of 8.3% [15][16] - Weiming Environmental Protection achieved a revenue of 5.88 billion yuan in the first three quarters of 2025, with a net profit of 2.14 billion yuan, marking a year-on-year increase of 1.14% [22][23] - Sany Heavy Industry's revenue for 2024 was reported at 77.77 billion yuan, with a year-on-year increase of 6.22%, and a net profit of 5.98 billion yuan, reflecting a growth of 31.98% [33][35] Group 4 - The report outlines a growth strategy for Tianshan Aluminum, focusing on its integrated aluminum industry chain and cost advantages from self-supplied power generation [15][19] - Weiming Environmental Protection's new material business has begun to generate revenue and profit, indicating a potential second growth curve for the company [22][25] - Sany Heavy Industry's global strategy has shown significant results, with international revenue accounting for 63.98% of total revenue, reflecting a strong performance in overseas markets [33][35] Group 5 - The report provides a detailed earnings forecast for the selected stocks, indicating expected growth rates and profitability for the upcoming years [8][19][22] - The growth and value portfolios have been adjusted for November, highlighting companies with strong fundamentals and market positions [4][8][19][22] - The report emphasizes the importance of monitoring market conditions and company performance to identify potential investment opportunities [3][9][11]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong outlook for the stock in the next six months [1]. Core Insights - The company has shown strong performance with a significant reduction in losses. In the first three quarters of 2025, it achieved revenue of 1.72 billion yuan, a year-on-year increase of 42.27%, and a net profit attributable to the parent company of -551 million yuan, narrowing losses by 48.60% [7]. - The commercialization of core products is accelerating, with new indications opening up growth potential. The sales of the core product, Tai Ta Xi Pu, have maintained high growth, particularly after the approval for myasthenia gravis in May [7]. - The company is optimizing expenses, with a notable decrease in R&D expenses due to overseas clinical trial costs being borne by partners [7]. Financial Performance Summary - Total revenue is projected to grow from 1.72 billion yuan in 2023 to 4.13 billion yuan by 2027, with a compound annual growth rate (CAGR) of approximately 30% [3][8]. - The net profit is expected to improve from -875 million yuan in 2025 to a positive 88 million yuan in 2027, indicating a turnaround in profitability [3][8]. - The earnings per share (EPS) is forecasted to move from -1.55 yuan in 2025 to 0.16 yuan in 2027, reflecting a significant recovery [3][8]. Product Development and Pipeline - The company is actively expanding its product pipeline, with several new indications for existing drugs showing promising results. The application for IgAN has been accepted, and positive results have been reported for the dry eye syndrome clinical trials [7]. - The collaboration with external partners is enhancing the efficiency of the R&D pipeline, with several products in advanced stages of clinical trials [7]. Market Position and Future Outlook - The company is positioned to benefit from the growing demand for its core products, with expectations of continued market expansion and improved operational efficiency [7]. - The report suggests that the company's strong performance and product pipeline warrant a "Buy" rating, reflecting confidence in its future growth trajectory [1][7].

Group 1 - The Hong Kong Stock Connect innovative drug sector experienced a significant rebound on November 3, with the innovative drug ETF (520880) showing a volatility of over 4.4% and a trading volume exceeding 500 million yuan, indicating strong bullish sentiment [1] - Key stocks such as Kangfang Biotech, Xiansheng Pharmaceutical, and Kangnuo Ya-B saw increases of nearly 6%, while other companies like Yuanda Pharmaceutical and Rongchang Biotech also experienced substantial gains [1] - The National Medical Insurance negotiation, which began on October 30, is expected to conclude with results announced in early December, introducing a new "commercial insurance innovative drug catalog" mechanism for the first time [1] Group 2 - Fund manager Feng Chen indicated that the innovative drug market could see a resurgence, suggesting that now may be a high-probability period for medium to long-term investments in innovative drugs [2] - The recent meeting between US and Chinese leaders has alleviated previous risks that suppressed the sector's performance, potentially allowing previously withdrawn funds to re-enter the market [2] - The current earnings season has shown strong performance from companies like Innovent Biologics and Hengrui Medicine, boosting confidence in the sector [2] Group 3 - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses entirely on innovative drug R&D companies, with over 70% of its holdings in large-cap innovative drug leaders [3] - As of the end of September, the index has seen a year-to-date increase of 108.14%, outperforming other innovative drug indices [3] - The ETF has a fund size of 1.806 billion yuan and an average daily trading volume of 493 million yuan, making it the largest and most liquid ETF tracking this index [3]

Core Insights - The foreign public funds have achieved significant excess returns due to proactive industry positioning and stable investment strategies, with some funds reporting returns exceeding 50% year-to-date [1][2] Group 1: Fund Performance - BlackRock Advanced Manufacturing Fund has a year-to-date return of 66.44%, with a heavy concentration in the manufacturing sector, accounting for 92.52% of its stock investments [2] - The top ten holdings of the BlackRock fund include companies like CATL and Hikvision, with notable stock price increases such as 176.76% for Zhongji Xuchuang [2] - The Robeco Resource Select Fund has achieved a year-to-date return of 79.00%, diversifying its investments across materials, mining, and energy sectors [2] Group 2: Market Outlook - Fund managers maintain a positive outlook for the fourth quarter, expecting low interest rates and ample liquidity to support the A-share market's medium to long-term performance [1][3] - Concerns about geopolitical factors and overseas policy rhythms may cause short-term disruptions, but the overall sentiment remains optimistic for quality technology and resource assets [3][5] - The managers of the BlackRock fund believe that the current low-growth macro environment will anchor a low-interest-rate scenario, pushing investors towards riskier assets with positive cash flows [4] Group 3: Strategic Adjustments - The funds have maintained relatively high positions while making flexible adjustments based on market changes, focusing on sectors like electronics and power equipment [3] - The Allianz China Select Fund has a year-to-date return of 54.48%, with significant holdings in manufacturing and healthcare, reflecting confidence in China's technological innovation [3] - The Robeco fund has strategically included upstream industries related to the current technology innovation cycle, aiming for future gains [5][6]

Core Viewpoint - Rongchang Biologics reported significant revenue growth and improved financial performance in Q3 2025, alongside the acceptance of its innovative drug application for IgA nephropathy, indicating strong potential in the biopharmaceutical market [1][2]. Financial Performance - For Q3 2025, the company achieved revenue of 6.22 billion yuan, a year-on-year increase of 33.13% - The net profit attributable to shareholders was -1.01 billion yuan, a reduction in losses by 65.24% year-on-year and a 48.25% decrease in losses compared to the previous quarter - The overall gross margin for the first three quarters was 84.27%, up by 4.51 percentage points year-on-year, while the operating cash flow net amount was 2.17 billion yuan, an increase of 125.99% year-on-year [1]. Product Development and Approvals - The company’s innovative drug, Tai A, for treating IgA nephropathy, has been accepted for priority review by the National Medical Products Administration, marking it as the first domestic original drug in this field [1]. - The company is advancing multiple clinical trials for Tai A in various autoimmune diseases, with results published in top medical journals [2]. - The company’s dual-target fusion protein, RC28-E, has been licensed to a Japanese company, generating upfront payments and potential milestone payments totaling up to 10.45 billion yuan [3]. Future Projections - Revenue projections for 2025 to 2027 are 22.5 billion yuan, 28.7 billion yuan, and 36.3 billion yuan, respectively, with year-on-year growth rates of 31.1%, 27.5%, and 26.6% - The net profit attributable to shareholders is expected to improve from -7.6 billion yuan in 2025 to 0.7 billion yuan in 2027, reflecting a significant turnaround in profitability [3].

港股创新药概念股走强，荣昌生物涨超9%，信达生物涨超8%，复星医药、君实生物、昭衍新药涨超 5%。 ...

Core Points - The Hang Seng Index closed at 25,906.65 points, down 1.43% [1] - The Hang Seng Tech Index closed at 5,908.08 points, down 2.37% [1] Company Performance - Semiconductor stocks led the decline, with Hua Hong Semiconductor falling over 7% and SMIC down over 5% [1] - Major tech stocks also experienced losses, with Alibaba down over 4%, Tencent Holdings down over 3%, and JD Group and Baidu Group both down over 2% [1] Sector Performance - The pharmaceutical and biotechnology sector saw gains, with Innovent Biologics rising over 7%, and Fosun Pharma and Rongchang Biologics both increasing over 6% [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported significant improvement in financial conditions, with a notable increase in revenue and a reduction in net losses. For Q3 2025, the revenue was 6.22 billion yuan, up 33.13% year-on-year, while the net loss was reduced by 65.24% year-on-year [1][2][3] - The company’s innovative drug, Tai'ai (泰它西普), has received acceptance for its market application for treating primary immunoglobulin A nephropathy, marking it as the first domestic original drug in this field [2] - The company is advancing its IO+ADC pipeline, with multiple research achievements published in top journals, indicating strong collaborative progress [3][8] Financial Performance Summary - For the first three quarters of 2025, the company achieved a gross margin of 84.27%, an increase of 4.51 percentage points year-on-year. The operating cash flow was 2.17 billion yuan, up 125.99% year-on-year [3] - The projected revenues for 2025 to 2027 are 22.5 billion, 28.7 billion, and 36.3 billion yuan, respectively, with year-on-year growth rates of 31.1%, 27.5%, and 26.6% [11] - The company expects to reduce net losses significantly, with projections of -7.6 million, -4.8 million, and 0.7 million yuan for the same period [11] Pipeline and Clinical Development - The company is actively pursuing new indications for its main commercial product, Tai'ai, with applications for dry syndrome and systemic lupus erythematosus already accepted [8] - The ADC product, Vidisicimab, has shown promising results in clinical trials for treating urinary tract cancer, with data presented at major medical conferences [8][10] - The dual-target fusion protein RC28-E is in advanced stages of clinical trials, indicating a robust pipeline for future growth [8][10]

Market Overview - The Hang Seng Index fell by 0.89%, down 232 points, closing at 26,050 points, while the Hang Seng Tech Index dropped by 1.91% [1] - The early trading volume in the Hong Kong stock market reached HKD 142.3 billion [1] Biotechnology Sector - The Hang Seng Biotechnology Index rebounded by 2.16%, with notable gains in several stocks: - InnoCare Pharma (09606) surged by 10.88% - 3SBio (01530) increased by over 10% - Innovent Biologics rose by 6.82% - Kelun-Biotech (06990) gained 5.69% [1] - Fosen Pharmaceuticals (01652) saw a significant increase, with a peak rise of nearly 74% and an early gain of 59.42% following the approval of Enzalutamide soft capsules and the potential selection of Metformin and Empagliflozin for national procurement [1] - Rongchang Biopharma (09995) rose by 6.75%, reporting a 40% year-on-year revenue growth and a significant reduction in losses for the first three quarters [1] Medical Sector - Spring Medical (01858) increased by over 21%, turning a profit of HKD 77.06 million in the third quarter as the company actively expands its international market [2] New Stocks Performance - Newly listed Dipo Technology (01384) continued to rise, gaining 18.97% and doubling its stock price within three days of listing [3] Financial Sector - China Everbright Bank (06818) fell by 5% post-earnings, with both revenue and profit declining in the third quarter, facing pressure from fair value changes [4] Other Notable Stocks - Huahao Zhongtian Pharmaceutical-B (02563) experienced a significant drop of over 37% due to a large unlock of shares after one year of listing [5] - Lion Holdings (02562) plummeted over 24% to a new low, planning to issue convertible bonds to raise approximately HKD 260 million for investments in gold and related products [6] - Air China (00753) dropped over 8%, with a more than 11% decline in net profit for the third quarter, and plans to raise up to HKD 20 billion through A-share placement [7]